Gene: SNX13
Official Full Name: sorting nexin 13provided by HGNC
Gene Summary: This gene encodes a PHOX domain- and RGS domain-containing protein that belongs to the sorting nexin (SNX) family and the regulator of G protein signaling (RGS) family. The PHOX domain is a phosphoinositide binding domain, and the SNX family members are involved in intracellular trafficking. The RGS family members are regulatory molecules that act as GTPase activating proteins for G alpha subunits of heterotrimeric G proteins. The RGS domain of this protein interacts with G alpha(s), accelerates its GTP hydrolysis, and attenuates G alpha(s)-mediated signaling. Overexpression of this protein delayes lysosomal degradation of the epidermal growth factor receptor. Because of its bifunctional role, this protein may link heterotrimeric G protein signaling and vesicular trafficking. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO29777 | SNX13 Knockout cell line (HeLa) | Human | SNX13 | 1:3~1:6 | Negative | Online Inquiry |
KO29778 | SNX13 Knockout cell line (HCT 116) | Human | SNX13 | 1:2~1:4 | Negative | Online Inquiry |
KO29779 | SNX13 Knockout cell line (HEK293) | Human | SNX13 | 1:3~1:6 | Negative | Online Inquiry |
KO29780 | SNX13 Knockout cell line (A549) | Human | SNX13 | 1:3~1:4 | Negative | Online Inquiry |
SNX13 Gene Knockout Cell Lines are expertly developed cellular models that allow researchers to study the biological impact of SNX13 gene deletion. The SNX13 gene is implicated in the regulation of intracellular trafficking and endocytosis, and these knockout cell lines create a valuable tool for examining the effects of loss-of-function mutations in various biological pathways. By utilizing CRISPR/Cas9 gene editing technology, these cell lines are genetically modified to efficiently disrupt the SNX13 gene, facilitating researchers to explore the resultant phenotypic alterations in cellular behavior.
The fundamental function of SNX13, which includes sorting and transporting proteins within the cellular milieu and participating in vesicle trafficking processes, provides a mechanism through which its knockout can reveal insights into cellular homeostasis and signaling pathways. In both research and clinical contexts, these cell lines serve as pivotal resources for elucidating the role of SNX13 in diseases, including metabolic disorders and cancers, where disrupted endocytic pathways might play a role.
What sets SNX13 Gene Knockout Cell Lines apart from alternative products is their reliability and reproducibility, derived from robust genetic modification techniques. These lines offer the benefit of well-characterized genomic backgrounds that allow for comparability across experimental conditions, which is critical for validating scientific hypotheses.
For researchers and clinicians, the ability to study specific gene effects in a controlled environment significantly accelerates the discovery of therapeutic targets and enhances the understanding of disease mechanisms. Utilizing these knockout cell lines aligns with the contemporary push towards precision medicine, emphasizing the importance of gene function in clinical scenarios.
At our company, expertise in genetic engineering and cell line development ensures that every product, including SNX13 Gene Knockout Cell Lines, meets the highest standards of quality and reliability, empowering scientific advancements and therapeutic developments.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.